Liraglutide is an injectable prescription medicine used: along with diet and exercise to lower blood sugar (glucose) in adults and children who are 10 years of age and older with type 2 diabetes ...

Lupin has received approval from the Food and Drug Administration for liraglutide injection single-patient-use prefilled pens and glucagon for injection vials. Both of these products will be ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®. Liraglutide is ...

Credit: Teva. The generic product is supplied in a prefilled, single-patient-use pen. The generic product is supplied in a prefilled, single-patient-use pen. Teva has launched an authorized generic ...

In a global move, Indian pharmaceutical company, Lupin on Friday has launched a generic diabetes medication in the US market. It has launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients with type 2 diabetes as a complement to diet and exercise. The FDA today ...

(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...